{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:10:02Z","timestamp":1792271402271,"version":"4.4.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody-drug conjugates (ADCs) have redefined the treatment of urothelial carcinoma (UC). However, the spatiotemporal heterogeneity and co-expression landscapes of these targets across diverse anatomical sites and pathological stages remain poorly understood. This study aimed to map these patterns and explore their clinical implications for personalized ADC therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of 118 UC specimens was analyzed, including matched pairs of primary tumors with adjacent normal tissues (n=60), carcinoma\n                      <jats:italic>in situ<\/jats:italic>\n                      (CIS, n=8), and lymph node (LN) metastases (n=12). Expression levels were evaluated via immunohistochemistry (IHC). Statistical analyses included the Wilcoxon signed-rank test, Mann\u2013Whitney U test, and multivariable logistic regression. A novel \u0394score (tumor score - normal score) was introduced to quantify target \u201cnet gain.\u201d\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High expression (IHC 2+ or higher) of at least one target occurred in 90.7 percent of patients, with 56.8 percent showing multi-target co-expression. HER2 and Trop-2 were significantly upregulated during the transition from CIS to invasive carcinoma (P\u00a0=\u00a00.034 and P\u00a0=\u00a00.039). While primary tumors and metastases showed global stability (P greater than 0.05), Nectin-4 tended to downregulate in metastases (negative ranks in 50 percent of pairs). Trop-2 expression was significantly higher in the lower than the upper urinary tract (P\u00a0=\u00a00.042), whereas HER2 and Nectin-4 were uniformly distributed. Furthermore, a high \u0394-Trop-2 was independently associated with muscle invasion, lymphovascular invasion, and metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the \u201cpost-EV+P\u201d era, our findings reveal significant antigenic drift and anatomical expression biases during disease progression, advocating for dynamic, multi-site molecular profiling over static primary-site assessment. This provides a translational blueprint to optimize ADC sequencing and overcome heterogeneity-driven resistance. Finally, we introduce the novel \u0394score as a new metric for further testing in quantifying net antigenic gain and predicting aggressive phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1887794","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:51:45Z","timestamp":1783486305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Shaobo","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Dai","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Hu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pain Treatment, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040187","article-title":"Real-world clinical outcomes with first-line systemic treatment and avelumab maintenance in US patients with locally advanced or metastatic urothelial carcinoma: the SPEAR Bladder-II study","volume":"32","author":"Sura","year":"2025","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.70077","article-title":"Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy","volume":"12","author":"Shi","year":"2026","journal-title":"J Pathol Clin Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15042-7","article-title":"Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs","volume":"25","author":"Kanaan","year":"2025","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16146","article-title":"Immunohistochemical analysis of HER2, EGFR, and Nectin-4 expression in upper urinary tract urothelial carcinoma","volume":"43","author":"Hashimoto","year":"2023","journal-title":"Anticancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance","volume":"29","author":"Aggen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:52:01Z","timestamp":1783486321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1887794"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1887794","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1887794"}}